Somapacitan - Novo Nordisk
Alternative Names: Albumin-binding somatropin - Novo Nordisk; Growth hormone derivative - Novo Nordisk; Long-acting growth hormone - Novo Nordisk; Long-acting somatropin - Novo Nordisk; NN 8640; NNC-0195-0092; Sogroya; Somatropin derivative - Novo Nordisk; Somatropin long acting - Novo NordiskLatest Information Update: 21 Oct 2025
At a glance
- Originator Novo Nordisk
- Class Growth hormones; Hormonal replacements; Tetrazoles
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Yes - Somatotropin deficiency
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Somatotropin deficiency
Most Recent Events
- 15 Oct 2025 Launched for Somatotropin deficiency (In children, In adults) in Canada (SC)
- 12 Jul 2025 Efficacy and adverse events data from a phase III REAL 9 trial in Somatotropin deficiency presented at the 107th Annual Meeting of the Endocrine Society (ENDO-2025)
- 12 Jul 2025 Efficacy and safety data from phase II REAL5 trial for Somatotropin deficiency presented at the 107th Annual Meeting of the Endocrine Society (ENDO-2025)